Aspire Growth Partners LLC Makes New $421,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aspire Growth Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 591 shares of the biopharmaceutical company's stock, valued at approximately $421,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Wilmington Savings Fund Society FSB increased its holdings in Regeneron Pharmaceuticals by 193.4% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 1,810 shares of the biopharmaceutical company's stock worth $1,903,000 after purchasing an additional 1,193 shares during the period. Tidal Investments LLC increased its stake in shares of Regeneron Pharmaceuticals by 8.7% during the third quarter. Tidal Investments LLC now owns 6,350 shares of the biopharmaceutical company's stock worth $6,675,000 after buying an additional 510 shares during the period. Synovus Financial Corp raised its holdings in Regeneron Pharmaceuticals by 3.4% in the third quarter. Synovus Financial Corp now owns 1,881 shares of the biopharmaceutical company's stock valued at $1,977,000 after acquiring an additional 61 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Finally, Everence Capital Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.4% in the 4th quarter. Everence Capital Management Inc. now owns 3,831 shares of the biopharmaceutical company's stock valued at $2,729,000 after purchasing an additional 90 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $605.61 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market cap of $66.21 billion, a price-to-earnings ratio of 15.82, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The firm's fifty day moving average price is $626.49 and its 200 day moving average price is $711.45. Regeneron Pharmaceuticals, Inc. has a 1-year low of $525.99 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Analyst Ratings Changes

Several research firms have recently issued reports on REGN. Royal Bank of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a research report on Wednesday. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a report on Monday, March 31st. TD Cowen decreased their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.